The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
In some organisms, notably birds, and ornithischian dinosaurs, portions of the tendon can become ossified. In this process, osteocytes infiltrate the tendon and lay down bone as they would in sesamoid bone such as the patella. In birds, tendon ossification primarily occurs in the hindlimb, while in ornithischian dinosaurs, ossified axial muscle tendons form a latticework along the neural and haemal spines on the tail, presumably for support.
=== Chemical === Americium metal readily reacts with oxygen and dissolves in aqueous acids. The most stable oxidation state for americium is +3. The chemistry of americium(III) has many similarities to the chemistry of lanthanide(III) compounds. For example, trivalent americium forms insoluble fluoride, oxalate, iodate, hydroxide, phosphate and other salts. Compounds of americium in oxidation states +2, +4, +5, +6 and +7 have also been studied. This is the widest range that has been observed with actinide elements. The color of americium compounds in aqueous solution is as follows: Am3+ (yellow-reddish), Am4+ (yellow-reddish), AmVO+2; (yellow), AmVIO2+2 (brown) and AmVIIO5−6 (dark green). The absorption spectra have sharp peaks, due to f-f transitions' in the visible and near-infrared regions. Typically, Am(III) has absorption maxima at ca. 504 and 811 nm, Am(V) at ca. 514 and 715 nm, and Am(VI) at ca. 666 and 992 nm. Americium compounds with oxidation state +4 and higher are strong oxidizing agents, comparable in strength to the permanganate ion (MnO−4) in acidic solutions. Whereas the Am4+ ions are generally unstable in solutions and readily convert to Am3+, compounds such as americium dioxide (AmO2) and americium(IV) fluoride (AmF4) are stable in the solid state. The pentavalent oxidation state of americium was first observed in 1951. In acidic aqueous solution the AmO+2 ion is unstable with respect to disproportionation. The reaction
=== Potential use of MRI/fMRI in diagnosis === In 2018, the American Psychological Association commissioned a review to reach a consensus on whether modern clinical MRI/fMRI will be able to be used in the diagnosis of mental health disorders. The criteria presented by the APA stated that the biomarkers used in diagnosis should:
=== Raw survey data === Topographic survey information is historically based upon the notes of surveyors. They may derive naming and cultural information from other local sources (for example, boundary delineation may be derived from local cadastral mapping). While of historical interest, these field notes inherently include errors and contradictions that later stages in map production resolve.
Sources: en.wikipedia.org
=== Casein allergy === A small fraction of the population is allergic to casein. Casein intolerance, also known as "milk protein intolerance", is experienced when the body cannot break down the proteins of casein. The prevalence of casein allergy or intolerance ranges from 0.25% to 4.9% of young children. Numbers for older children and adults are not known. Casein that is heat-treated has been shown to be more allergenic and harder to digest when fed to infants. Breast milk has not been shown to cause an allergic reaction typically, but should be administered to an infant with caution each time in case of adverse reaction from something the breastfeeding parent consumed that contained casein. Following a casein-free diet has been shown to improve outcomes of infants who are breastfed while allergic or intolerant to dairy protein. Supplementation of protease enzyme has been shown to help casein intolerant individuals digest the protein with minimal adverse reaction.
Although an adult bear is quite capable of killing a human, American black bears typically avoid confronting humans. Unlike grizzly bears, which became a subject of fearsome legend among the European settlers of North America, black bears were rarely considered overly dangerous, even though they lived in areas where the pioneers had settled. American black bears rarely attack when confronted by humans and usually only make mock charges, emit blowing noises and swat the ground with their forepaws. The number of attacks on humans is higher than those by brown bears in North America, but this is largely because black bears considerably outnumber brown bears. Compared to brown bear attacks, aggressive encounters with black bears rarely lead to serious injury. Most attacks tend to be motivated by hunger rather than territoriality and thus victims have a higher probability of surviving by fighting back rather than submitting. Unlike female brown bears, female American black bears are not as protective of their cubs and rarely attack humans in the vicinity of the cubs. However, occasionally such attacks do occur. The worst recorded attack occurred in May 1978, in which a bear killed three teenagers fishing in Algonquin Provincial Park in Ontario. Another exceptional attack occurred in August 1997 in Liard River Hot Springs Provincial Park in British Columbia, when an emaciated bear attacked a mother and child, killing the mother and a man who intervened. The bear was shot while mauling a fourth victim.
== Physiology == The activation of protein C is strongly promoted by thrombomodulin and endothelial protein C receptor (EPCR), the latter of which is found primarily on endothelial cells (cells on the inside of blood vessels). The presence of thrombomodulin accelerates activation by several orders of magnitude, and EPCR speeds up activation by a factor of 20. If either of these two proteins is absent in murine specimens, the mouse dies from excessive blood-clotting while still in an embryonic state. On the endothelium, APC performs a major role in regulating blood clotting, inflammation, and cell death (apoptosis). Because of the accelerating effect of thrombomodulin on the activation of protein C, the protein may be said to be activated not by thrombin but the thrombin–thrombomodulin (or even thrombin–thrombomodulin–EPCR) complex. Once in active form, APC may or may not remain bound to EPCR, to which it has approximately the same affinity as the protein zymogen. Protein C in zymogen form is present in normal adult human blood plasma at concentrations between 65 and 135 IU/dL. Activated protein C is found at levels approximately 2000 times lower than this. Mild protein C deficiency corresponds to plasma levels above 20 IU/dL, but below the normal range. Moderately severe deficiencies describe blood concentrations between 1 and 20 IU/dL; severe deficiencies yield levels of protein C that are below 1 IU/dL or are undetectable. Protein C levels in a healthy term infant average 40 IU/dL.
=== Pharmacology === A drug's distribution coefficient strongly affects how easily the drug can reach its intended target in the body, how strong an effect it will have once it reaches its target, and how long it will remain in the body in an active form. Hence, the log P of a molecule is one criterion used in decision-making by medicinal chemists in pre-clinical drug discovery, for example, in the assessment of druglikeness of drug candidates. Likewise, it is used to calculate lipophilic efficiency in evaluating the quality of research compounds, where the efficiency for a compound is defined as its potency, via measured values of pIC50 or pEC50, minus its value of log P.
The CJNG are fighting the Nueva Plaza Cartel for control of Guadalajara; La Unión Tepito for Mexico City; Los Viagras and La Familia Michoacana for the states of Michoacán and Guerrero; Los Zetas in the states of Veracruz and Puebla; Cártel del Noreste in Zacatecas; the Sinaloa Cartel in Baja California, Sonora, Ciudad Juárez, Zacatecas and Chiapas; as well as the Santa Rosa de Lima Cartel in Guanajuato. They have an alliance with the Cártel del Golfo in Zacatecas and La Línea in Juárez. CJNG is considered by the Mexican government to be one of the most dangerous criminal organizations in Mexico and the most powerful drug cartel in Mexico. It is also considered the cartel with the most paramilitary firepower. CJNG is heavily militarized and more violent than other criminal organizations. It has a special operations group known as the Grupo Élite for specific types of warfare. Its hitman training program is strict and professional. The cartel is best known for its fights against the Zetas and Templarios, it has fought La Resistencia for control of Aguililla, Michoacán, and its surrounding territories. In later time, it would be revealed that a major part of El Mencho's influence in the CJNG actually came through his marriage to Rosalinda González Valencia, herself highly involved in drug trafficking. From 2018 to 2020, the CJNG engaged in 298 reported acts of gang-related violence, more than any other cartel.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.